PHAR vs. TRMD

Last updated Apr 2, 2026

Compare and contrast key facts about Pharming Group NV (PHAR) and TORM plc (TRMD).

Performance

PHAR vs. TRMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pharming Group NV (PHAR) and TORM plc (TRMD). The values are adjusted to include any dividend payments, if applicable.

PHAR vs. TRMD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
PHAR Pharming Group NV	-4.24%	75.56%	-11.94%	3.63%	23.38%	-41.16%	-9.01%
TRMD TORM plc	46.83%	11.21%	-23.37%	31.64%	297.66%	12.91%	-2.62%

Fundamentals

Market Cap PHAR : $1.28B TRMD : $2.79B
EPS PHAR : $0.03 TRMD : $2.85
PE Ratio PHAR : 582.13 TRMD : 9.82
PS Ratio PHAR : 3.28 TRMD : 2.10
PB Ratio PHAR : 5.44 TRMD : 1.27
Total Revenue (TTM) PHAR : $360.18M TRMD : $1.34B
Gross Profit (TTM) PHAR : $317.87M TRMD : $582.69M
EBITDA (TTM) PHAR : $30.81M TRMD : $580.07M

Returns By Period

In the year-to-date period, PHAR achieves a -4.24% return, which is significantly lower than TRMD's 46.83% return.

PHAR

• 1D: 1.68%
• 1M: 5.82%
• YTD: -4.24%
• 6M: 9.94%
• 1Y: 96.21%
• 3Y*: 7.82%
• 5Y*: 5.27%
• 10Y*: —

TRMD

• 1D: 0.39%
• 1M: -7.08%
• YTD: 46.83%
• 6M: 38.47%
• 1Y: 87.27%
• 3Y*: 12.60%
• 5Y*: 41.23%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PHAR vs. TRMD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PHAR

PHAR Risk / Return Rank: 81
PHAR Sharpe Ratio Rank: 82
PHAR Sortino Ratio Rank: 78
PHAR Omega Ratio Rank: 75
PHAR Calmar Ratio Rank: 86
PHAR Martin Ratio Rank: 85

TRMD

TRMD Risk / Return Rank: 90
TRMD Sharpe Ratio Rank: 92
TRMD Sortino Ratio Rank: 89
TRMD Omega Ratio Rank: 85
TRMD Calmar Ratio Rank: 92
TRMD Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PHAR vs. TRMD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pharming Group NV (PHAR) and TORM plc (TRMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PHAR	TRMD	Difference
Sharpe ratio Return per unit of total volatility	1.41	2.22	-0.82
Sortino ratio Return per unit of downside risk	2.06	2.83	-0.77
Omega ratio Gain probability vs. loss probability	1.26	1.34	-0.08
Calmar ratio Return relative to maximum drawdown	3.25	4.46	-1.21
Martin ratio Return relative to average drawdown	8.02	11.70	-3.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PHAR vs. TRMD - Sharpe Ratio Comparison

The current PHAR Sharpe Ratio is 1.41, which is lower than the TRMD Sharpe Ratio of 2.22. The chart below compares the historical Sharpe Ratios of PHAR and TRMD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PHAR	TRMD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.41	2.22	-0.82
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.08	0.90	-0.83
Sharpe Ratio (All Time) Calculated using the full available price history	0.00	0.48	-0.48

Correlation

The correlation between PHAR and TRMD is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PHAR vs. TRMD - Dividend Comparison

PHAR has not paid dividends to shareholders, while TRMD's dividend yield for the trailing twelve months is around 7.57%.

	TTM	2025	2024	2023	2022	2021	2020
PHAR Pharming Group NV	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TRMD TORM plc	7.57%	10.32%	30.13%	23.05%	6.99%	0.00%	14.89%

Drawdowns

PHAR vs. TRMD - Drawdown Comparison

The maximum PHAR drawdown since its inception was -60.45%, roughly equal to the maximum TRMD drawdown of -60.59%. Use the drawdown chart below to compare losses from any high point for PHAR and TRMD.

Drawdown Indicators

	PHAR	TRMD	Difference
Max Drawdown Largest peak-to-trough decline	-60.45%	-60.59%	+0.14%
Max Drawdown (1Y) Largest decline over 1 year	-31.49%	-19.49%	-12.00%
Max Drawdown (5Y) Largest decline over 5 years	-57.32%	-60.59%	+3.27%
Current Drawdown Current decline from peak	-20.11%	-13.10%	-7.01%
Average Drawdown Average peak-to-trough decline	-34.38%	-22.91%	-11.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.75%	7.43%	+5.32%

Volatility

PHAR vs. TRMD - Volatility Comparison

Pharming Group NV (PHAR) and TORM plc (TRMD) have volatilities of 14.94% and 15.01%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PHAR	TRMD	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.94%	15.01%	-0.07%
Volatility (6M) Calculated over the trailing 6-month period	48.88%	26.37%	+22.51%
Volatility (1Y) Calculated over the trailing 1-year period	68.86%	39.46%	+29.40%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.02%	45.88%	+23.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	67.87%	60.24%	+7.63%

Financials

PHAR vs. TRMD - Profitability Comparison

The chart below illustrates the profitability comparison between Pharming Group NV and TORM plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PHAR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pharming Group NV reported a gross profit of 72.63M and revenue of 90.58M. Therefore, the gross margin over that period was 80.2%.

TRMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, TORM plc reported a gross profit of 134.80M and revenue of 354.98M. Therefore, the gross margin over that period was 38.0%.

PHAR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pharming Group NV reported an operating income of 1.70M and revenue of 90.58M, resulting in an operating margin of 1.9%.

TRMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, TORM plc reported an operating income of 98.16M and revenue of 354.98M, resulting in an operating margin of 27.7%.

PHAR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pharming Group NV reported a net income of 4.51M and revenue of 90.58M, resulting in a net margin of 5.0%.

TRMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, TORM plc reported a net income of 87.39M and revenue of 354.98M, resulting in a net margin of 24.6%.